BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 1557042)

  • 1. Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region.
    Michaelsen TE; Aase A; Norderhaug L; Sandlie I
    Mol Immunol; 1992 Mar; 29(3):319-26. PubMed ID: 1557042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge.
    Michaelsen TE; Brekke OH; Aase A; Sandin RH; Bremnes B; Sandlie I
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9243-7. PubMed ID: 7937748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The functional activity of Fc gamma RII and Fc gamma RIII on subsets of human lymphocytes.
    Hadley AG; Zupanska B; Kumpel BM; Leader KA
    Immunology; 1992 Jul; 76(3):446-51. PubMed ID: 1356095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FcγR Binding and ADCC Activity of Human IgG Allotypes.
    de Taeye SW; Bentlage AEH; Mebius MM; Meesters JI; Lissenberg-Thunnissen S; Falck D; Sénard T; Salehi N; Wuhrer M; Schuurman J; Labrijn AF; Rispens T; Vidarsson G
    Front Immunol; 2020; 11():740. PubMed ID: 32435243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca
    Freitas Monteiro M; Papaserafeim M; Réal A; Puga Yung GL; Seebach JD
    J Leukoc Biol; 2020 Oct; 108(4):1409-1423. PubMed ID: 32620047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human IgG3 is decreased and IgG1, IgG2 and IgG4 are unchanged in molecular size by mild reduction and reoxidation without any major change in effector functions.
    Michaelsen TE; Naess LM; Aase A
    Mol Immunol; 1993 Jan; 30(1):35-45. PubMed ID: 8417373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating antibody-dependent cellular cytotoxicity of epidermal growth factor receptor-specific heavy-chain antibodies through hinge engineering.
    D'Eall C; Pon RA; Rossotti MA; Krahn N; Spearman M; Callaghan D; van Faassen H; Hussack G; Stetefeld J; Butler M; Durocher Y; Zhang J; Henry KA; Tanha J
    Immunol Cell Biol; 2019 Jul; 97(6):526-537. PubMed ID: 30680791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of complement by an IgG molecule without a genetic hinge.
    Brekke OH; Michaelsen TE; Sandin R; Sandlie I
    Nature; 1993 Jun; 363(6430):628-30. PubMed ID: 8510754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide.
    Preston MJ; Gerçeker AA; Reff ME; Pier GB
    Infect Immun; 1998 Sep; 66(9):4137-42. PubMed ID: 9712759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human IgG3 can adopt the disulfide bond pattern characteristic for IgG1 without resembling it in complement mediated cell lysis.
    Brekke OH; Bremnes B; Sandin R; Aase A; Michaelsen TE; Sandlie I
    Mol Immunol; 1993 Nov; 30(16):1419-25. PubMed ID: 8232327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro functional activity of IgG1 and IgG3 polyclonal and monoclonal anti-D.
    Kumpel BM
    Vox Sang; 1997; 72(1):45-51. PubMed ID: 9031501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence of ovine Ig gamma 2 constant region heavy chain cDNA and molecular modelling of ruminant IgG isotypes.
    Clarkson CA; Beale D; Coadwell JW; Symons DB
    Mol Immunol; 1993 Sep; 30(13):1195-204. PubMed ID: 8413324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses.
    McCloskey N; Turner MW; Steffner P; Owens R; Goldblatt D
    Immunology; 1996 Jun; 88(2):169-73. PubMed ID: 8690447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural difference in the complement activation site of human IgG1 and IgG3.
    Michaelsen TE; Sandlie I; Bratlie DB; Sandin RH; Ihle O
    Scand J Immunol; 2009 Dec; 70(6):553-64. PubMed ID: 19906198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hinge.
    Norderhaug L; Brekke OH; Bremnes B; Sandin R; Aase A; Michaelsen TE; Sandlie I
    Eur J Immunol; 1991 Oct; 21(10):2379-84. PubMed ID: 1915551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
    MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-dependent cell-mediated cytotoxicity (ADCC) toward human O+ red cells coated with anti-D antibody: comparison between lymphocyte and monocyte ADCC activity.
    Sunada M; Suzuki S; Ota Z
    Acta Med Okayama; 1985 Apr; 39(2):77-89. PubMed ID: 3923782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of the hinge region length in binding of human IgG to human Fcgamma receptors.
    Redpath S; Michaelsen TE; Sandlie I; Clark MR
    Hum Immunol; 1998 Nov; 59(11):720-7. PubMed ID: 9796740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADCC (K-cell) lysis of human erythrocytes sensitized with rhesus alloantibodies. III. Comparison of IgG anti-D agglutinating and lytic (ADCC) activity and the role of IgG subclasses.
    Urbaniak SJ; Greiss MA
    Br J Haematol; 1980 Nov; 46(3):447-53. PubMed ID: 6778497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C1q binding to chimeric monoclonal IgG3 antibodies consisting of mouse variable regions and human constant regions with shortened hinge containing 15 to 47 amino acids.
    Sandlie I; Aase A; Westby C; Michaelsen TE
    Eur J Immunol; 1989 Sep; 19(9):1599-603. PubMed ID: 2792180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.